Largest biotech by earnings
Net income for the latest fiscal year: what was left for shareholders after every cost, interest and tax. A negative figure is a loss.
Gilead Sciences leads the 24 biotech ranked by earnings, at CZK 189B, ahead of Amgen (CZK 171.3B) and Biogen (CZK 28.7B). Figures as of 18 Nov 2026, 15:00 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Gilead SciencesCZK 189B
- Median
- -CZK 1.5B
- Combined market value
- CZK 18.8T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Earnings ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | CZK 189B | CZK 4.67T | CZK 3,761.12 | 0.55% down | 33% up | ||
| 2 | AmgenAMGN · Health Care | CZK 171.3B | CZK 5.43T | CZK 10,041.18 | 1.28% down | 34% up | ||
| 3 | BiogenBIIB · Health Care | CZK 28.7B | CZK 822.5B | CZK 5,564.28 | 0.11% down | 49% up | ||
| 4 | argenxARGX · Health Care | CZK 28.7B | CZK 1.34T | CZK 21,364.20 | 1.51% up | 4% up | ||
| 5 | ExelixisEXEL · Health Care | CZK 17.4B | CZK 372.6B | CZK 1,526.84 | 0.35% up | 63% up | ||
| 6 | Neurocrine BiosciencesNBIX · Health Care | CZK 10.6B | CZK 370.8B | CZK 3,663.17 | 0.60% down | 20% up | ||
| 7 | QiagenQGEN · Health Care | CZK 9.4B | CZK 227.8B | CZK 1,103.26 | 0.16% down | 12% up | ||
| 8 | Halozyme TherapeuticsHALO · Health Care | CZK 7B | CZK 244.8B | CZK 2,146.77 | 0.71% up | 37% up | ||
| 9 | Krystal BiotechKRYS · Health Care | CZK 4.5B | CZK 202.3B | CZK 6,826.35 | 2.94% up | 46% up | ||
| 10 | Bio-TechneTECH · Health Care | CZK 4B | CZK 253.7B | CZK 1,615.13 | 0.12% up | 26% up | ||
| 11 | RepligenRGEN · Health Care | CZK 1.1B | CZK 243.1B | CZK 3,802.22 | 5.55% up | 5% up | ||
| 12 | Adaptive BiotechnologiesADPT · Health Care | -CZK 1.3B | CZK 103.5B | CZK 639.26 | 1.02% up | 88% up | ||
| 13 | Twist BioscienceTWST · Health Care | -CZK 1.7B | CZK 176.2B | CZK 2,583.79 | 3.86% up | 340% up | ||
| 14 | CG OncologyCGON · Health Care | -CZK 3.6B | CZK 154.8B | CZK 1,732.63 | 1.18% down | 85% up | ||
| 15 | Kodiak SciencesKOD · Health Care | -CZK 5.1B | CZK 142.5B | CZK 2,179.64 | 1.37% up | 396% up | ||
| 16 | Kymera TherapeuticsKYMR · Health Care | -CZK 6.9B | CZK 234.6B | CZK 2,748.38 | 1.82% up | 87% up | ||
| 17 | ImmunityBioIBRX · Health Care | -CZK 7.8B | CZK 151.9B | CZK 142.82 | 2.72% up | 193% up | ||
| 18 | Scholar Rock HoldingSRRK · Health Care | -CZK 8.4B | CZK 128.4B | CZK 1,052.06 | 5.07% up | 14% up | ||
| 19 | ImmunovantIMVT · Health Care | -CZK 11.2B | CZK 154.3B | CZK 745.76 | 1.10% up | 43% up | ||
| 20 | CRISPR TherapeuticsCRSP · Health Care | -CZK 12.9B | CZK 90.2B | CZK 930.01 | 4.28% up | 21% down | ||
| 21 | VaxcytePCVX · Health Care | -CZK 17B | CZK 208.5B | CZK 1,316.94 | 0.19% down | 22% up | ||
| 22 | Revolution MedicinesRVMD · Health Care | -CZK 25.1B | CZK 774.7B | CZK 3,581.65 | 0.89% down | 131% up | ||
| 23 | BioNTechBNTX · Health Care | -CZK 28B | CZK 468.2B | CZK 1,888.34 | 0.18% up | 16% down | ||
| 24 | ModernaMRNA · Health Care | -CZK 62.7B | CZK 1.83T | CZK 4,533.43 | 1.31% down | 755% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Earnings is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 22.2118 CZK).
Questions and answers
Which biotech rank first by earnings?
Gilead Sciences (CZK 189B), Amgen (CZK 171.3B) and Biogen (CZK 28.7B) are the top three of the 24 biotech ranked by earnings as of 18 Nov 2026, 15:00 UTC.
How many biotech are in this ranking?
24 are ranked by earnings.
What are these biotech worth together?
The 24 biotech ranked by earnings have a combined market value of CZK 18.8T as of 18 Nov 2026, 15:00 UTC.
What does ranking by earnings measure?
Net income for the latest fiscal year: what was left for shareholders after every cost, interest and tax. A negative figure is a loss.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest biotech by earnings”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=earnings
Underlying data: Yahoo Finance; SEC EDGAR.